Breast Ultrasound Recs May Not Be Targeting the Right Women It's not just dense breasts that matter, researchers say Jun 12, 2023
CAR-T for Chronic Lymphocytic Leukemia Hits Goal of Mid-Stage Trial All patients had progressed on BTK inhibitors and most had failed venetoclax Jun 12, 2023
Hooray! A Clearer Estimate of Your Risk for Death Is Here Researchers do the legwork to incorporate smoking status into NCI's "Know Your Chances" website Jun 09, 2023
TTFields Therapy Yields OS Improvement in Second-Line NSCLC However, device was not tested alongside current standard of care, expert points out Jun 08, 2023
How Vax Skeptics Sow Doubt; Gun Death Every 11 Minutes; 90210 Star's Cancer Spreads Health news and commentary from around the Web gathered by ทฌวัษ็ว๘ staff Jun 08, 2023
Studies Question Role of CDK4/6 Inhibitors in First-Line Advanced Breast Cancer No PFS, OS benefit with first-line versus second-line CDK4/6 inhibition, more toxicity, cost Jun 07, 2023
Skipping Radiotherapy 'Seems Safe' for PMBCL Patients in Remission PET-negative patients after chemoimmunotherapy fared well with observation alone Jun 07, 2023
FGFR Inhibitor Stakes Claim to Post-Anti-PD-1 Role in Advanced Bladder Cancer Survival benefit supports FGFR testing for all patients with metastatic disease, researcher says Jun 07, 2023
Checkpoint Blockade Stumbles in Advanced EGFR-Mutant NSCLC "Immediate changes" needed to patient care to avoid unnecessary toxicity, says ASCO expert Jun 07, 2023
Certain NSCLC Patients May Be Able to Stop Immunotherapy at 2 Years Retrospective study finds no difference in OS between patients who stop and those who continue Jun 06, 2023
No Survival Benefit With Immune Checkpoint Inhibitor Rechallenge in Metastatic RCC The strategy also led to increased toxicity Jun 06, 2023
New Data in NSCLC Bolster Support for Perioperative Immunotherapy EFS benefit with pembrolizumab in KEYNOTE-671, but no OS benefit "yet," says investigator Jun 05, 2023
Second-Line Axi-Cel Bests Standard in Relapsed/Refractory Large B-Cell Lymphoma The CAR T-cell therapy led to significantly longer overall survival Jun 05, 2023
New Agents for Relapsed/Refractory Myeloma Impress in Early-Stage Clinical Trials High rates of deep, durable response with bispecific antibody, rapidly produced CAR T-cell agents Jun 05, 2023
CAR-T Tops Standard Care in Heavily Pretreated Lenalidomide-Refractory Myeloma Ciltacabtagene autoleucel improved progression-free survival versus two standard triplets Jun 05, 2023
Omitting RT Safe in Many Locally Advanced Rectal Cancers Most intermediate-risk cases can be cured without pelvic radiation, says investigator Jun 05, 2023
Novel IDH1/2 Inhibitor Shows 'Dramatic Effect' in Low-Grade Glioma INDIGO data demonstrate that some patients can delay "toxic" chemo and radiation, says expert Jun 04, 2023
Nivolumab-AVD Boosts PFS in Untreated Hodgkin Lymphoma SWOG trial had goal of "harmonizing" treatment in adults, children with advanced-stage disease Jun 04, 2023
New Standard in Operable EGFR-Positive Lung Cancer "We should firmly close the door on one-size-fits-all treatment," says ASCO expert Jun 04, 2023
How a Medical Recoding May Limit Cancer Patientsโ Options for Breast Reconstruction Many believe this would restrict women's options for surgery Jun 04, 2023
New Ovarian Cancer Drug Extends Survival in Resistant Disease "Practice changing" findings for tough-to-treat patient population Jun 04, 2023
Neoadjuvant Chemo Flops Versus Upfront Surgery for Resectable Pancreatic Cancer Survival 13 months better with surgery, but "curiosities" in neoadjuvant arm muddy the results Jun 04, 2023
Novel Anti-HER2 Drugs 'Impressive' in Advanced Biliary Cancer Response rates reached 41-47% with different approaches in rare disease Jun 03, 2023
Chemo-Free Approach Works in Subset of Patients With HER2+ Early Breast Cancer Impressive 3-year invasive DFS seen with adaptive response strategy using FDG-PET Jun 03, 2023
Pricey Drug Combo Boosts PFS in First-Line Advanced Ovarian Cancer Questions about anti-PD-L1 contribution, cost, and access to durvalumab, bevacizumab, olaparib Jun 03, 2023
De-Escalated Surgery Suffices for Low-Risk Cervical Cancer Simple hysterectomy non-inferior to radical operation Jun 02, 2023
CDK4/6 Extends Reach Into Early-Stage Breast Cancer Addition of ribociclib to endocrine therapy boosts disease-free survival in high-risk disease Jun 02, 2023
Adaptive RT Fails to Relieve Dry Mouth in Head and Neck Cancer "Expensive and intensive" process does not translate into clinical benefit, researchers conclude Jun 01, 2023
No Access to Routine Healthcare Biggest Barrier to HPV Vaccination Retrospective analysis shows vaccination rates haven't much improved for women since 2015 May 25, 2023
Medicaid Expansion Tied to Better Outcomes in Black Patients With GI Cancers Two-year mortality decreased for three types of GI cancer in expansion vs non-expansion states May 25, 2023
Less-Invasive Surgery for Pancreatic Cancer Proves Safe, Effective Radical resection rate noninferior to open surgery in early-stage disease, with similar survival May 25, 2023
Monoclonal Antibody Reduced Need For Transfusions in Low-Risk MDS Results suggest a "paradigm shift" in the treatment of anemia for these patients May 25, 2023
Cross-Border Collaboration Improves Survival in Pediatric Leukemia Patients 5-year OS increased to 100% in standard-risk ALL patients at a Tijuana hospital May 25, 2023
Trial Results Spark Talk of Curing More Metastatic Cervical Cancers Adding pembrolizumab to standard care extends overall survival by a year May 25, 2023
Lung Cancer Screening Results Influence Follow-Up Adherence Study suggests groups to target for enhanced outreach to encourage regular screening May 25, 2023
Warning: Prior Auth for Colonoscopy Is the Wrong Way to Go The policy adds delays to care and may worsen health outcomes May 24, 2023
What to Know About Hank Green's Hodgkin's Lymphoma Diagnosis Hodgkin's is one of the more rare lymphomas, but tends to be very treatable May 24, 2023
Anti-EGFR Rechallenge Boosts PFS in Third-Line Metastatic Colorectal Cancer ctDNA-identified wild-type tumors benefited most from adding panitumumab to standard therapy May 23, 2023
Lumpers vs Splitters: Categorizing Prostate Cancer Should very low-risk and low-risk be combined into one? May 19, 2023
Return of Rule Nixing Delivery of Rx Drugs to Medicare Patients Drawing Docs' Ire "It is endangering the lives of the oldest and sickest Americans," oncology group says May 18, 2023
